Clinical Takeaway
Clinical trials show that cannabis-based products containing THC provide modest reductions in chronic pain compared to placebo, though the overall quality of evidence remains low to moderate. The benefit appears to vary based on the THC-to-CBD ratio, the source of the cannabinoid, and how it is administered. Patients and clinicians should weigh these incremental gains against known risks, recognizing that current evidence does not yet support strong universal recommendations.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This systematic review addresses a critical gap in evidence regarding cannabinoid efficacy and safety for chronic pain management, which affects millions of patients seeking alternatives to opioids and other conventional analgesics. By synthesizing data from randomized controlled trials stratified by THC-to-CBD ratios, the study provides clinicians with pharmacologically relevant guidance for determining which cannabinoid formulations may offer therapeutic benefit while minimizing adverse effects. Given the regulatory and clinical uncertainty surrounding cannabis-based medicines, this updated evidence synthesis enables more informed decision-making for patient selection and product selection in chronic pain management algorithms.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
? This updated systematic review provides timely evidence on cannabinoid efficacy for chronic pain, yet clinicians should recognize that heterogeneity in THC-to-CBD ratios, delivery methods, dosing protocols, and patient populations significantly limits the ability to draw definitive conclusions about which formulations work best for specific pain conditions. The quality of evidence remains constrained by small sample sizes, short trial durations, and inconsistent outcome measures across studies, making it difficult to distinguish true therapeutic benefit from placebo response or to predict individual patient response. Additionally, most randomized controlled trials exclude patients with comorbid substance use disorders, psychiatric conditions, or those taking multiple medications, which limits generalizability to real-world clinical populations who often present with these complexities. Despite these limitations, this synthesis can help guide informed shared decision-making conversations with patients interested in cannabis-based treatments by clarifying where evidence exists versus where uncertainty persists. In practice, I recommend using this review to support conservative, individualized trials in carefully selected patients with inadequate response to
Have thoughts on this? Share it:
